Amalgamated Bank’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,757
| Closed | -$281K | – | 3028 |
|
|
2023
Q2 | $281K | Sell |
2,757
-997
| -27% | -$94.3K | ﹤0.01% | 1693 |
|
|
2023
Q1 | $341K | Sell |
3,754
-509
| -12% | -$29.9K | ﹤0.01% | 1587 |
|
|
2022
Q4 | $162K | Hold |
4,263
| – | – | ﹤0.01% | 1939 |
|
|
2022
Q3 | $107K | Buy |
4,263
+56
| +1% | +$1.55K | ﹤0.01% | 2119 |
|
|
2022
Q2 | $128K | Sell |
4,207
-111
| -3% | -$3.31K | ﹤0.01% | 2075 |
|
|
2022
Q1 | $141K | Buy |
+4,318
| New | +$128K | ﹤0.01% | 2073 |
|
|
2021
Q4 | – | Sell |
-4,715
| Closed | -$474K | – | 2184 |
|
|
2021
Q3 | $474K | Sell |
4,715
-296
| -6% | -$34.7K | ﹤0.01% | 1606 |
|
|
2021
Q2 | $709K | Buy |
5,011
+327
| +7% | +$36.9K | 0.01% | 1456 |
|
|
2021
Q1 | $467K | Buy |
4,684
+20
| +0.4% | +$2.33K | 0.02% | 1023 |
|
|
2020
Q4 | $577K | Sell |
4,664
-4
| -0.1% | -$526 | 0.02% | 889 |
|
|
2020
Q3 | $455K | Sell |
4,668
-40
| -0.8% | -$5K | 0.02% | 894 |
|
|
2020
Q2 | $735K | Buy |
4,708
+958
| +26% | +$146K | 0.03% | 581 |
|
|
2020
Q1 | $541K | Sell |
3,750
-116
| -3% | -$22.4K | 0.01% | 868 |
|
|
2019
Q4 | $790K | Buy |
3,866
+663
| +21% | +$121K | 0.01% | 903 |
|
|
2019
Q3 | $257K | Sell |
3,203
-50
| -2% | -$4.24K | 0.01% | 1412 |
|
|
2019
Q2 | $307K | Buy |
3,253
+322
| +11% | +$27.8K | 0.01% | 1340 |
|
|
2019
Q1 | $251K | Buy |
+2,931
| New | +$243K | 0.01% | 1374 |
|
Other funds holding RETA
Amalgamated Bank's RETA Position: Q3 2023 in Review
Amalgamated Bank sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,757 shares — an estimated $281K sold.
Amalgamated Bank first reported a position in RETA in Q1 2019 and held it in 17 quarters. The position peaked at $790K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Amalgamated Bank reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Amalgamated Bank sold 2,757 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $281K.
- Amalgamated Bank first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 17 quarters.
- Amalgamated Bank's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $790K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Amalgamated Bank's 13F filing for Q3 2023, filed 8 Nov 2023.